Drug Profile
Emodepside - Bayer HealthCare
Alternative Names: BAY 44-4400; Macrofilaricide - Bayer Healthcare/Drugs for Neglected Diseases Initiative FoundationLatest Information Update: 27 Sep 2022
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Bayer HealthCare; Bill & Melinda Gates Foundation; Drugs for Neglected Diseases Initiative Foundation
- Class Anthelmintics; Depsipeptides; Skin disorder therapies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hookworm infections
- No development reported Filariasis; Onchocerciasis
Most Recent Events
- 05 Sep 2022 Swiss Tropical & Public Health Institute plans a phase II trial for Hookworm infections in Tanzania (NCT05538767)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Filariasis(In volunteers) in United Kingdom (PO, Immediate release)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Filariasis(In volunteers) in United Kingdom (PO, Liquid)